KRW 4585.0
(-1.4%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 26.91 Billion KRW | -23.91% |
2022 | 35.37 Billion KRW | 27.56% |
2021 | 27.73 Billion KRW | 5.21% |
2020 | 26.36 Billion KRW | 112.55% |
2019 | 12.4 Billion KRW | 24.38% |
2018 | 9.97 Billion KRW | 225.49% |
2017 | 3.06 Billion KRW | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 4.72 Billion KRW | -49.15% |
2024 Q1 | 9.28 Billion KRW | 28.8% |
2023 Q4 | 7.2 Billion KRW | 25.24% |
2023 FY | 26.91 Billion KRW | -23.91% |
2023 Q3 | 5.75 Billion KRW | -20.37% |
2023 Q2 | 7.22 Billion KRW | 7.44% |
2023 Q1 | 6.72 Billion KRW | -50.09% |
2022 Q2 | 6.7 Billion KRW | -30.42% |
2022 FY | 35.37 Billion KRW | 27.56% |
2022 Q3 | 5.55 Billion KRW | -17.15% |
2022 Q4 | 13.47 Billion KRW | 142.58% |
2022 Q1 | 9.63 Billion KRW | 55.55% |
2021 Q1 | 5.22 Billion KRW | 64709.96% |
2021 Q3 | 8.61 Billion KRW | 11.91% |
2021 Q2 | 7.7 Billion KRW | 47.5% |
2021 Q4 | 6.19 Billion KRW | -28.09% |
2021 FY | 27.73 Billion KRW | 5.21% |
2020 Q3 | 8.33 Million KRW | 0.0% |
2020 FY | 26.36 Billion KRW | 112.55% |
2020 Q4 | 8.05 Million KRW | -3.37% |
2019 FY | 12.4 Billion KRW | 24.38% |
2018 FY | 9.97 Billion KRW | 225.49% |
2017 FY | 3.06 Billion KRW | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
HLB Co., Ltd. | 109.98 Billion KRW | 75.525% |
iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -243.105% |
BINEX Co., Ltd. | 55.67 Billion KRW | 51.65% |
Bioneer Corporation | 204.55 Billion KRW | 86.84% |
Anterogen.Co.,Ltd. | 7.74 Billion KRW | -247.787% |
MEDIPOST Co., Ltd. | 65.31 Billion KRW | 58.785% |
CrystalGenomics, Inc. | 32.36 Billion KRW | 16.838% |
Helixmith Co., Ltd | 37.36 Billion KRW | 27.96% |
Chabiotech Co.,Ltd. | 285.93 Billion KRW | 90.586% |
Medy-Tox Inc. | 110.88 Billion KRW | 75.723% |
Peptron, Inc. | 16.65 Billion KRW | -61.614% |
Amicogen, Inc. | 52.82 Billion KRW | 49.039% |
Genexine, Inc. | 41.62 Billion KRW | 35.334% |
HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -66.514% |
LegoChem Biosciences, Inc. | 98.61 Billion KRW | 72.704% |
ALTEOGEN Inc. | 40.93 Billion KRW | 34.239% |
PharmaResearch Co., Ltd. | 89.44 Billion KRW | 69.903% |
SillaJen, Inc. | 5.11 Billion KRW | -426.567% |
JETEMA, Co., Ltd. | 25.66 Billion KRW | -4.89% |
OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 23.632% |
Genomictree Inc. | 16.26 Billion KRW | -65.506% |
D&D Pharmatech | 32.16 Billion KRW | 16.304% |
EASY BIO,Inc. | 29.67 Billion KRW | 9.277% |
GI Innovation, Inc. | 57.59 Billion KRW | 53.259% |